Moneycontrol Be a Pro
Get App
Last Updated : Mar 01, 2017 10:54 AM IST | Source:

Buy Sanofi India; target of Rs 5330: Centrum

Centrum is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 5330 in its research report dated February 28, 2017.

  • bselive
  • nselive
Todays L/H

Centrum's report on Sanofi India

The launch of new anti-diabetic products and line extensions are likely to drive future growth. We expect improved performance due to continued strong growth of its six flagship brands which grew faster than the market growth. SIL is among the top picks in the pharma sector.


We retain our Buy rating on Sanofi India (SIL) and revise our TP to Rs 5,330 (earlier Rs 5,880) based on 25x December’18E EPS of Rs 213.4. SIL’s results for Q4CY16 were below our expectations and were impacted by demonetisation. The company’s revenue increased 4% YoY, margin declined 180bps to 18.1% and net profit fell 4%.

For all recommendations, click here

The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.
First Published on Mar 1, 2017 10:54 am
Follow us on
Available On
PCI DSS Compliant